intimation about the Notice Pertaining to discrepancies by Government of Maharashtra department of Goods and service Tax
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sandu Pharmaceuticals has received a notice from the Maharashtra Goods & Service Tax Department (Office of the Deputy Commissioner of State Tax) flagging discrepancies in its GST returns. The issue relates to non-reversal of Input Tax Credit (ITC) of Rs. 13,00,679 in GSTR3B as compared with GSTR9 for FY2023-24. The notice was issued under Rule 99(1) of the Maharashtra GST Rules, 2017, and was received on 22 December 2025. The company plans to file a reply to the tax authority. Based on its own assessment and legal advice, management expects a favorable outcome and has stated there will be no impact on the company's financials, operations, or other activities.
The monetary exposure is small at around Rs. 13 lakhs relative to a listed pharma company. Management has publicly stated no material impact is expected, so this is likely a minor compliance matter rather than a significant risk to shareholders.